Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7842| Effectiveness of a nation-wide COVID-19 vaccination program in Mexico | |
| CLEMENTE HUMBERTO ZÚÑIGA GIL CHRISTIAN ARTURO ZARAGOZA JIMÉNEZ EDGAR GABRIEL GARCIA RODRIGUEZ Omar Yaxmehen Bello-Chavolla Neftali Eduardo Antonio Villa Sergio Iván Valdés-Ferrer Daniel Ramírez García Luisa Fernández Chirino Carlos Fermín Martínez Javier Mancilla-Galindo Ashuin Kammar-García José Alberto AVILA-FUNES Miguel García-Grimshaw Santa Elizabeth Ceballos Liceaga Guillermo Carbajal Sandoval Ricardo Cortes-Alcala Gustavo Reyes-Terán Hugo López-Gatell Ramírez Luis Miguel Gutiérrez Robledo José Antonio Montes González | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| https://doi.org/10.1101/2022.04.04.22273330 | |
| BACKGROUND Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac vaccines, against SARS-CoV-2 infection, COVID-19 related hospitalization and death for adults ≥18 years in Mexico. VE was estimated using Cox proportional hazard models considering time-varying vaccination status in partial and fully vaccinated individuals compared to unvaccinated adults, adjusted by age, sex, comorbidities and municipality. We also estimated VE for adults ≥60 years, for cases with diabetes and comparing periods with predominance of variants B.1.1.519 and B.1.617.2. RESULTS We assessed 793,487 vaccinated compared to 4,792,338 unvaccinated adults between December 24th, 2020, and September 27th, 2021. VE against SARS-CoV-2 infection was highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95%CI 90.3-92.4) and Ad26.COV2.S (82.2%, 95%CI 81.4-82.9), whereas for COVID-19 related hospitalization were BNT162b2 (84.3%, 95%CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95%CI 79.5-83.1) and for mortality BNT162b2 (89.8%, 95%CI 89.2-90.2) and mRNA-12732 (93.5%, 95%CI 86.0-97.0). VE for all evaluated vaccines was reduced for adults ≥60 years, people with diabetes, and in periods of Delta variant predominance. CONCLUSIONS All evaluated vaccines were effective against SARS-CoV-2 infection and COVID-19 related hospitalization and death. Mass vaccination campaigns with multiple vaccine products are feasible and effective to maximize vaccination coverage. | |
| Medrxiv | |
| 05-04-2022 | |
| Preimpreso | |
| medrxiv.org/ | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Effectiveness of a nation-wide COVID-19 vaccination program in Mexico.pdf | 396.5 kB | Adobe PDF | Visualizar/Abrir |